December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Profound Medical Corp. - common stock (NQ:PROF)

6.835 +0.105 (+1.56%)
Streaming Delayed Price Updated: 1:35 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Profound Medical Corp. - common stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoring 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Q1 Earnings Call Highlights ↗
Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use,... 
Via MarketBeat
Topics Earnings
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Profound Medical Reports Strong First Quarter 2026 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
From Pomerantz LLP
Via GlobeNewswire
News headline image
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
From Profound Medical Corp.
Via GlobeNewswire
News headline image
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
From Profound Medical Corp.
Via GlobeNewswire
Here are the top movers in Friday's session. ↗
Via Chartmill
News headline image
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Announces Upcoming Investor Events
From Profound Medical Corp.
Via GlobeNewswire
News headline image
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care 
From Profound Medical Corp.
Via GlobeNewswire
InvestorNewsBreaks – Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) Closes $36 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Profound Medical Corp. Announces Closing of Private Placement
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Announces Upsize of Private Placement
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Financing included participation by healthcare-dedicated investors alongside existing shareholders 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Financing included participation by healthcare-dedicated investors alongside existing shareholders 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Reports Strong Third Quarter 2025 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation
– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy 
From Profound Medical Corp.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.